New research led by Stony Brook Medicine and Yale School of Medicine reveals Keratin 17 (K17) as a key driver for chemoresistance to gemcitabine in pancreatic cancer.
A team of national cancer researchers, including Drs. Kenneth Shroyer and Natalia Marchenko from Stony Brook Medicine, and Dr. Luisa Escobar-Hoyos from Yale School of Medicine, have made significant findings regarding the role of Keratin 17 (K17) in pancreatic cancer. Their study discovered that K17 plays a crucial part in promoting chemoresistance to gemcitabine, an agent commonly used for treating various cancers, including advanced stages of pancreatic, lung, and breast tumors.
These results underscore the importance of K17 as a potential therapeutic target for developing new treatments aimed at tackling the most aggressive forms of cancer. Identifying K17's role in chemoresistance could pave the way for more effective strategies to combat this deadly disease.
